Insider Buying: Mesa Laboratories, Inc. (MLAB) Director Buys 30,000 Shares of Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director Seg Ventures, Llc bought 30,000 shares of the stock in a transaction on Friday, October 12th. The shares were acquired at an average cost of $21.52 per share, with a total value of $645,600.00. Following the purchase, the director now owns 120,000 shares of the company’s stock, valued at approximately $2,582,400. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Seg Ventures, Llc also recently made the following trade(s):

  • On Friday, December 21st, Seg Ventures, Llc bought 40,000 shares of Mesa Laboratories stock. The shares were acquired at an average cost of $24.75 per share, with a total value of $990,000.00.
  • On Sunday, December 30th, Seg Ventures, Llc bought 20,000 shares of Mesa Laboratories stock. The shares were acquired at an average cost of $23.10 per share, with a total value of $462,000.00.

Shares of NASDAQ MLAB opened at $181.50 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.10 and a quick ratio of 1.55. The stock has a market cap of $693.18 million, a price-to-earnings ratio of 29.37 and a beta of 0.24. Mesa Laboratories, Inc. has a 12 month low of $122.35 and a 12 month high of $224.95.

Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Tuesday, July 31st. The medical instruments supplier reported $1.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.27. The firm had revenue of $25.14 million during the quarter. Mesa Laboratories had a positive return on equity of 15.92% and a negative net margin of 0.25%. On average, sell-side analysts predict that Mesa Laboratories, Inc. will post 7.09 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 17th. Shareholders of record on Friday, November 30th will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.35%. The ex-dividend date is Thursday, November 29th. Mesa Laboratories’s payout ratio is 10.36%.

Hedge funds and other institutional investors have recently modified their holdings of the business. Conestoga Capital Advisors LLC increased its stake in shares of Mesa Laboratories by 4.9% in the second quarter. Conestoga Capital Advisors LLC now owns 428,722 shares of the medical instruments supplier’s stock valued at $90,495,000 after buying an additional 19,845 shares during the period. BlackRock Inc. increased its stake in shares of Mesa Laboratories by 11.3% in the second quarter. BlackRock Inc. now owns 210,585 shares of the medical instruments supplier’s stock valued at $44,449,000 after buying an additional 21,299 shares during the period. Royce & Associates LP increased its stake in shares of Mesa Laboratories by 18.2% in the second quarter. Royce & Associates LP now owns 102,430 shares of the medical instruments supplier’s stock valued at $21,621,000 after buying an additional 15,778 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in shares of Mesa Laboratories in the second quarter valued at approximately $12,064,000. Finally, Northern Trust Corp increased its stake in shares of Mesa Laboratories by 7.2% in the second quarter. Northern Trust Corp now owns 48,167 shares of the medical instruments supplier’s stock valued at $10,167,000 after buying an additional 3,222 shares during the period. 71.91% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have commented on MLAB shares. TheStreet raised Mesa Laboratories from a “c” rating to a “b” rating in a research note on Thursday, June 28th. BidaskClub downgraded Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 18th. Zacks Investment Research raised Mesa Laboratories from a “hold” rating to a “buy” rating and set a $248.00 target price for the company in a research note on Wednesday, July 11th. Finally, ValuEngine downgraded Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th.

About Mesa Laboratories

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

Further Reading: What is a put option?

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply